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S R M P N A 
ATAGCCGAATGCCGAATGCG 
P L D C Q L 
CACCGTTAGATTGCCAGTTA 
S D D L Q K 
TTAGTGACGATTTGCAAAAA 
K A R N K R 
GTAAAGCACGAAACAAGCGG 
I D S L L L 
AGATCGACAGCCTCTTATTG 
I V N R V H 
GTATCGTGAATCGAGTACAT 
T P I G G E 
AAACCCCAATCGGCGGTGAG 
S T E L I G 
AATCGACCGAACTCATCGGC 
AGCAAAGAGGGGTCGGGGGA 
GGCGTTGTTAAATCTCCCCT 
M P T G I I 
TTATATGTTCACAGGTATTA 
E F A V V T I 
CGAATTTGCGGTAGTCACAA 
T I A V N G V 
CACGATTGCGGTGAACGGCG 
A D V M S E T 
CGCCGATGTAATGTCGGAAA 
P V N L E R A 
TCCGGTTAA'I'I‘TAGAACGCG 
G H I D G T G 
GGGGCATATTGACGGCACCG 
Y R I K T S P 
GTATCGCATTAAAACCTCTC 
I D G I S L T 
CATTGACGGTATTAGCCTGA 
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K Q P V R I V 
AAACAACCGGTCCGGATTGT 
V Q T A K E Y 
GTGCAGACAGCGAAAGAATA 
I E Q F R P L 
ATTGAACAATTTAGACCGCT 
V D L Q D L L 
GTAGAT'I‘TGCAAGATC'I'I‘TT 
E G G S S L N 
GAAGGCGGTTCAAGTTTGAA 
C Y I A P K L 
TGTTATATTGCGCCTAAATT 
G I Q Q I D Q 
GGAATTCAACAAATCGACCA 
E D I L L D Y 
GAAGATATTTTGTTGGATTA 
GATTTGAGATAATGTTGAAA 
AACCCCTCTTTACAAAAGAG 
E E V G K I 
TTGAAGAAGTCGGCAAAATT 
N A T K V L 
TTAATGCGACCAAAGTATTA 
C L T V T S 
TATGTTTAACCGTAACTTCT 
L K R T S L 
CGTTAAAACGTACTTCATTA 
M A A N G R 
CGATGGCGGCAAACGGACGT 
E I A E I T 
GCGAAATTGCGGAAATCACA 
K L M R Y I 
CAAAATTAATGCGTTATATT 
V V D T D D 
CCGTAGTCGATACCGATGAT 
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CTGCGATAGCCAATTACGTA 
R T V I A T V 
TCGCACCGTAATTGCAACCG 
G V D V L V C 
TGGCGTAGATGTATTAGTGT 
Q K L G E M Q 
GCAAAAGCTCGGTGAAATGC 
F S A L E S G 
TTTCAGTGCGTTAGAAAGCG 
V G G K Q A K 
AGTCGGTGGTAAACAAGCGA 
A V K L K L K 
AGCGGTTAAATTAAAATTGA 
V V I S P L * 
TGTAGTCATCTCCCCTCTTT 
TTTACACCGCCTTTCACTTT 
AGGGATCAATAATGAGGAAA 
A Q I H K Q G 
GCTCAAATTCATAAGCAAGG 
Q D V H L G D 
CAAGACGTTCATTTAGGCGA 
F S S N Q P T 
TTTTCGAGTAATCAGTTTAC 
G E L K S N S 
GGCGAATTAAAGTCGAATAG 
F G G H I V S 
TTCGGCGGACACATCGTTTC 
P A H N S T W 
CCGGCACATAATTCGACATG 
I E K G S I T 
ATTGAGAAAGGTTCGATCAC 
E S F R V S I 
GAAAGTTTCCGTGTATCGAT 
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E Q E G R G V 
TGAGCAAGAGGGCAGAGGTG 
I N K L R A Y 
AATCAATAAGCTACGTGCTT 
V A L G F K E 
CGTCGCTTTAGGATTTAAAG 
Q L G V K S I 
GCAGTTAGGCGTAAAATCGA 
K E Q G L N I 
AAAAGAGCAAGGATTAAATA 
D I D Y L K V 
TGACATTGATTACCTAAAAG 
TTAACAACCGTATGTAGTAT 
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I L Y L R Q 
TGA'I'TCTGTATTTACGCCAA 
E L Q D K G 
ACGAACTACAAGATAAAGGG 
D S R E Y Y 
AAGACGAACGTGAGTACTAT 
R L L T N N 
TCCGTTTATTAACCAATAAT 
V A R E P I 
TCGTTGCACGTGAGCCGATT 
K Q I K M G 
TCAAACAGATAAAAATGGGG 
TAGGGAAGCAAGCGTTGCGT 
-10 
AGCGGTCACT'I‘TTTTATAAA ATTTTGCATATTTCGAGAGG ACAAAAAAATGGCAAAGATT 
T G N L V A T 
ACAGGTAACTTAGTTGCGAC 
F I N D K L L 
TTTATCAACGATAAATTATT 
E N D I D T A 
GAAAACGATATTGATACGGC 
K M A N S G K 
AAAATGGCAAACAGCGGTAA 
S T T H Y D Y 
TCGACAACTCACTATGATTA 
L E T G V P V 
TTAGAAACCGGCGTACCGGT 
I E R A G T K 
ATTGAACGCGCGGGTACTAA 
E I V N V L K 
GAAATAGTAAACGTATTAAA 
G L K F G I V 
AGGTTTAAAATTCGGTATTG 
S G A I D T L 
AAGCGGTGCAATTGATACGT 
W V P G A F E 
ATGGGTTCCGGGTGCATTTG 
Y D A V I C L 
ATATGATGCGGTAATCTGTT 
V C N E A A K 
CGTATGTAATGAAGCGGCAA 
I F G V L T T 
AATTTTCGGTGTATTAACCA 
A G N K G S E 
AGCAGGTAATAAAGGTTCAG 
A I * 
AGCGATCTAATTTTCGTTTG 
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E G R G I G L 
GAAGGTCGTGGTATCGGTTT 
M D T V E A N 
ATGGATACCGTTGAAGCGAA 
I G A Q M F Q 
ATCGGTGCACAAATGTTCCA 
P A K I E G L 
CCGGCAAAAATTGAAGGCTT 
I V E P N K N 
ATTGTAGAACCGAACAAAAA 
N M F N F * 
CATATGTTTAACTTCTAACT 
-35 
CCCTACTATAGAATGATACA 
M A K I 
T A R F N D 
TAACCGCACGTTTCAACGAT 
V R H G A Y 
TAGTGCGTCACGGTGCGTAT 
I P L V A K 
AGATTCCATTAGTTGCGAAA 
G T V I R G 
TAGGTACGGTAATTCGCGGT 
G I G A V A 
AAGGTATCGGTGCGGTAGCA 
E N I E Q A 
CAGAAAATATTGAACAGGCG 
C A L G A I 
AATGTGCATTAGGCGCAATC 
<———--— 
ACGTGCTAAAAACAAGCGGT 
4201 CGTTTTTGACTGGAATTTTG CAAAT'I‘TCCCGTTAAAAACG 
4253 AGTAAAGACCTTCTTTCTCG TACCAGATTTTGTTGATATA 
FIG. 40 
ACCGCTTATATT'I‘TATGTCT 
TAGCAAGCTTGG 4312 
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VACCINES OF PASTEURELLACEAE 
MUTANTS AND VACCINATION METHOD 
CROSS REFERENCE TO RELATED CASES 
This application is a divisional of application Ser. No. 
08/741,327, ?led on Oct. 28, 1996 now US. Pat. No. 
5,925,354, Which includes the disclosure in provisional 
patent application serial No. 60/007,764 ?led Nov. 30, 1995, 
for Characterization of Actinobacillus pleuropneumoniae 
Ribo?avin Biosynthesis Genes, hereby incorporated by ref 
erence. 
TECHNICAL FIELD 
The invention relates to vaccines and in particular, live 
vaccines against Actinobacillus pleuropneumoniae (APP) 
and related bacterial pathogens. The invention is also con 
cerned With recombinant techniques for preparing such a 
vaccine. 
BACKGROUND OF THE INVENTION 
An organism knoWn as Actinobacillus pleuropneumoniae 
(APP) is a gram negative coccobacillus organism that is 
found in the pig and causes pneumonia in the pig. 
This disease is characteristically an acute necrotiZing 
hemorrhagic bronchopneumonia, With accompanying ?brin 
ous pleuritis (FenWick, B. and S. Henry. 1994. Porcine 
pleuropneumonia. J. Am. Vet. Med. Assoc. 204:1334—1340) 
(Sebunya, T. N. K. and J. R. Saunders. 1983. Haemophilus 
pleuropneumoniae infection in swim: a revieW. J. Am. Vet. 
Med. Assoc. 182:1331—1337). Porcine pleuropneumonia is 
an economically devastating, severe and often fatal disease 
With clinical courses ranging from hyperacute to chronic 
infection (FenWick, B. and S. Henry. 1994. Porcine pleu 
ropneumonia. J. Am. Vet. Med. Assoc. 204:1334—1340) 
(Hunneman, W. A. 1986. Incidence, economic effects, and 
control of Haemophilus pleuropneumoniae infections in 
pigs. Vet. Quarterly 8:83—87). The existence of at least 
tWelve antigenically distinct capsular serotypes (Perry, M. 
B., E. Altman, J.-R. Brisson, L. M. Beynon, and J. C. 
Richards. 1990. Structural characteristics of the antigenic 
capsular polysaccharides and lipopolysaccharides involved 
in the serological classi?cation of Actinobacillus pleurop 
neumoniae strains. Serodiag. Immunother. Infect. Dis. 
4:299—308) has made development of a cross-protective 
vaccine dif?cult. Killed Whole cell bacterins provide at best 
serotype-speci?c protection (Nielsen, R. 1984. Haemophilus 
pleuropneumoniae serotypes—Cross protection experi 
ments. Nord. Vet. Med. 36:221—234) (Nielsen, R. 1976. 
Pleuropneumonia of sWine caused by Haemophilus pleu 
ropneumoniae. Studies on the protection obtained by vac 
cination. Nord. Vet. Med. 28:337—338) (Rosendal, S., D. S. 
Carpenter, W. R. Mitchell, and M. R. Wilson. 1981. Vacci 
nation against pleuropneumonia in pigs caused by Haemo 
philus pleuropneumoniae. Can. Vet. J. 22:34—35) (Thacker, 
B. J., and M. H. Mulks. 1988. Evaluation of commercial 
Haemophilus pleuropneumoniae vaccines. Proc. Int. Pig 
Vet. Soc. 10:87). In contrast, natural or experimental infec 
tion With a highly virulent serotype ofA. pleuropneumoniae 
elicits protection against reinfection With any serotype 
(Nielsen, R. 1979. Haemophilus parahaemolyticus sero 
types: pathogenicity and cross immunity. Nord. Vet. Med. 
31:407—413) (Nielsen, R. 1984. Haemophilus pleuropneu 
moniae serotypes—Cross protection experiments. Nord. 
Vet. Med. 36:221—234) (Nielsen, R. 1974. Serological and 
immunological studies of pleuropneumonia of sWine caused 
by Haemophilus parahaemolyticus. Acta Vet. Scand. 
10 
15 
25 
35 
45 
55 
65 
2 
15:80—89). In several recent studies, attenuated strains of A. 
pleuropneumoniae produced by chemical nutagenesis, serial 
passage, or other unde?ned spontaneous mutation have been 
tested as live vaccines, With promising results (InZana, T. J ., 
J. Todd, and H. P. Veit. 1993. Safety, stability and ef?cacy of 
nonencapsulated mutants of Actinobacillus pleuropneumo 
niae for use in live vaccines. Infect. Immun. 61:1682—1686) 
(Paltineanu, D., R. Pambucol, E. TirZiu, and I. Scobercea. 
1992. SWine infectious pleuropneumonia: Aerosol vaccina 
tion With a live attenuated vaccine. Proc. Int. Pig. Vet. Soc. 
12:214) (Utrera, V., C. Pijoan, and T. Molitor. 1992. Evalu 
ation of the immunity induced in pigs after infection With a 
loW virulence strain of A. pleuropneumoniae serotype 1. 
Proc. Int. Pig. Vet. Soc. 12:213). HoWever, the use of live 
vaccines in the ?eld is problematic, particularly When the 
attenuating lesion in the vaccine strain has not been geneti 
cally de?ned. A Well-de?ned mutation that prevents rever 
sion to Wild-type Would be extremely desirable for the 
development of a live attenuated vaccine against Actinoba 
cillus pleuropneumoniae. 
A variety of mutations in biosynthetic pathWays are 
knoWn to be attenuating in other organisms. Lesions in 
aro(Hoiseth S. K. and B. A. D. Stocker. 1981. Aromatic 
dependent Salmonella typhimurium are non-virulent and 
effective as live vaccines. Nature (london). 291: 238—239) 
(Homchampa, P., R. A. Strugnell and B. Adler. 1992. 
Molecular analysis of the aroA gene of Pasteurella malto 
cida and vaccine potential of a constructed aroA mutant. 
Mol. Microbiol. 6: 3585—3593) (Homchampa, P., R. A. 
Strugnell and B. Adler. 1994. Construction and vaccine 
potential of an aroA mutant of Pasteurella haemolytica. Vet. 
Microbiol. 42:35—44) (Karnell, A., P. D. Cam, N. Verma and 
A. A. Lindberg. 1993. AroD deleteion attenuates Shigella 
?exneri strain 2457T and makes it a safe and efficacious oral 
vaccine in monkeys. Vaccine 8:830—836.) (Lindberg, A. A., 
A. Karnell, B. A. D. Stocker, S. Katakura, H. SWeiha and F. 
P. Reinholt. 1988. Development of an auxotrophic oral live 
Shigella ?exneri vaccine. Vaccine 6:146—150) 
(O’Callaghan, D. D. Maskell, F. Y. Lieu, C. S. F. Easmon 
and G. Dougan. 1988. CharacteriZation of aromatic and 
purine dependent Salmonella typhimurium: attenuation, per 
sistence and ability to induce protective immunity in 
BALB/c mice. Infect. Immun. 56:419—423) (Vaughan, L. 
M., P. R. Smith, and T. J. Foster. 1993. An aromatic 
dependent mutant of the ?sh pathogen Aeromonas salmo 
nicida is attenuated in ?sh and is effective as a live vaccine 
against the Salmonid disease furunculosis. Infect. Immun. 
61:2172—2181), pur (O’Callaghan, D. D. Maskell, F. Y. 
Lieu, C. S. F. Easmon and G. Dougan. 1988. CharacteriZa 
tion of aromatic and purine dependent Salmonella typhimu 
rium: attenuation, persistence and ability to induce protec 
tive immunity in BALB/c mice. Infect. Immun. 5 6:419—423) 
(SigWart, D. E, B. A. D. Stocker, and J. D. Clements. 1989. 
Effect of a purA mutation on the ef?cacy of Salmonella live 
vaccine vectors. Infect. Immun. 57:1858—1861), and thy 
(Ahmed, Z. U., M. R. Sarker, and D. A. Sack. 1990. 
Protection of adult rabbits and monkeys from lethal shigello 
sis by oral immuniZation With a thymine-requiring and 
temperature-sensitive mutant of Shigella ?exneri Y. Vaccine. 
8:153—158) loci, Which affect the biosynthesis of aromatic 
amino acids, purines, and thymine, respectively, are attenu 
ating because they eliminate the ability of the bacterium to 
synthesiZe critical compounds that are not readily available 
Within mammalian hosts. For example, aro mutants of 
Salmonella and Shigella species have been shoWn to be 
attenuated in their natural hosts (Hoiseth S. K. and B. A. D. 
Stocker. 1981. Aromatic-dependent Salmonella typhimu 
US 6,410,021 B1 
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rium are non-virulent and effective as live vaccines. Nature 
(london). 291: 238—239) (Homchampa, P., R. A. Strugnell 
and B. Adler. 1992. Molecular analysis of the aroA gene of 
Pasteurella multocida and vaccine potential of a constructed 
aroA mutant. Mol. Microbiol. 6: 3585—3593) (Homchampa, 
P., R. A. Strugnell and B. Adler. 1994. Construction and 
vaccine potential of an aroA mutant of Pasteurella 
haemolytica. Vet. Microbiol. 42:35—44) (Karnell, A., P. D. 
Cam, N. Verma and A. A. Lindberg. 1993. AroD deletion 
attenuates Shigella ?exneri strain 2457T and makes it a safe 
and ef?cacious oral vaccine in monkeys. Vaccine 
8:830—836) (Lindberg, A. A., A. Karnell, B. A. D. Stocker, 
S. Katakura, H. SWeiha and F. P. Reinholt. 1988. Develop 
ment of an auxotrophic oral live Shigella ?exneri vaccine. 
Vaccine 6:146—150) (O’Callaghan, D. D. Maskell, F. Y. 
Lieu, C. S. F. Easmon and G. Dougan. 1988. CharacteriZa 
tion of aromatic and purine dependent Salmonella typhimu 
rium: attenuation, persistence and ability to induce protec 
tive immunity in BALB/c mice. Infect. Immun. 
56:419—423). Lesions that affect the biosynthesis of LPS 
(Collins, L. V., S. Attridge, and J. Hackett. 1991. Mutations 
at rfc or pmi attenuate Salmonella typhimurium virulence for 
mice. Infect. Immun. 59:1079—1085) (Nnalue, N. A., and B. 
A. D. Stocker. 1987. Tests of the virulence and live-vaccine 
ef?cacy of auxotrophic and gale derivatives of Salmonella 
cholerasuis. Infect. Immun. 55 :955—962) and of cyclic AMP 
(Kelly, S. M., B. A. Bosecker and R. Curtiss III. 1992. 
CharacteriZation and protective properties of attenuated 
mutants of Salmonella cholerasuis. Infect. Immun. 
60:4881—4890) (Tacket, C. I., D. M. Hone, R. Curtiss III, S. 
M. Kelly, G. Losonsky, L. Guers. A. M. Harris, R. Edelman. 
M. M. Levine. 1992. Comparison of the safety and immu 
nogenicity of AaroC AaroD and AcyaAcrp Salmonella typhi 
strains in adult volunteers. Infect. Immun. 60:536—541) have 
also been shoWn to be attenuating in Salmonella species. It 
is important to note that not all attenuating mutations are 
good vaccine candidates in different organisms because 
some attenuating mutations result in poor persistence and 
immunogenicity (O’Callaghan, D. D. Maskell, F. Y. Lieu, C. 
S. F. Easmon and G. Dougan. 1988. CharacteriZation of 
aromatic and purine dependent Salmonella typhimurium: 
attenuation, persistence and ability to induce protective 
immunity in BALB/c mice. Infect. Immun. 56:419—423) 
(SigWart, D. F., B. A. D. Stocker, and J. D. Clements. 1989. 
Effect of a purA mutation on the ef?cacy of Salmonella live 
vaccine vectors. Infect. Immun. 57:1858—1861). 
Ribo?avin (vitamin B2) , a precursor of the coenZymes 
?avin adenine dinucleotide (FAD) and ?avin mononucle 
otide (FMN), is essential for basic metabolism. It is synthe 
siZed by plants and by most microorganisms but not by 
higher animals (Bacher, A. 1991. Biosynthesis of ?avins. p. 
215—59. In F. Muller (ed.), Chemistry and Biochemistry of 
Flavins, Vol. 1. Chemical Rubber Company, Boca Raton, 
Fla.). Many pathogenic bacteria are apparently unable to 
utiliZe ?avins from their environment and are entirely 
dependent on endogenous production of ribo?avin (Schott, 
K., J. Kellerman, F. Lottspeich and A. Bacher. 1990. Ribo 
?avin syntheses of Bacillus subtilis: puri?cation and amino 
acid sequence of the ot-subunit. J. Biol.Chem. 
265:4204—4209). Even With the ability to utiliZe exogenous 
ribo?avin, there may not be enough of the vitamin present 
in mammalian host tissues to permit groWth, particularly not 
in sites devoid of normal bacterial ?ora. 
Vaccines are preparations used to prevent speci?c dis 
eases in animals by inducing immunity. This is accom 
plished by exposing a patient to an antigen from an agent 
capable of causing a particular disease Which, in turn, causes 
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the immune system of the patient to produce large Quantities 
of antibody. The presence of the antibody in the patient’s 
blood protects the patient from a later attack by the disease 
causing agent. Vaccines may either be composed of subunits 
of the agent, or the live or killed agent itself. If a live vaccine 
is to be used, its virulence must be attenuated in some Way; 
otherWise, the vaccine Will cause the disease it is intended to 
protect against. See US. Pat. No. 5,429,818, Col. 1. 
Most current vaccines against APP are killed Whole cell 
bacterins, that is, Whole bacterial cells killed by heat treat 
ment or formaliniZation, suspended in an adjuvant solution. 
Some alternative Ways of attempting to develop vaccines 
against APP are the use of subunit vaccines and the use of 
non-encapsulated mutants. 
The use of a protease lysate of the outer membrane of A. 
pleuropneumoniae cells as a vaccine against APP infection 
is described in US. Pat. No. 5,332,572. 
The use of extracellular proteins and/or hemolysins from 
APP as vaccines against APP infection is described in US. 
Pat. No. 5,254,340, WO Patent No. 9409821, EP No. 
595,188, CA 2045950, and EP No. 453,024. 
The use of non-encapsulated mutants of APP is described 
in US. Pat. No. 5,429,818. It disclosed that the capsule of 
such bacteria is required for virulence. Therefore, the prepa 
ration of a mutant of APP that Was a non-capsulated mutant 
Was described as a vaccine. 
A method of administering vaccines to pigs by a tran 
sthoracic intrapulmonary immuniZation is described in US. 
Pat. No. 5,456,914. 
A vaccine for the immuniZation of an individual against 
Salmonella choleraesuis utiliZing derivatives that are inca 
pable of producing functional adenylate cyclase and/or 
cyclic AMP receptor protein is described in US. Pat. No. 
5,468,485. The avirulent S. choleraesuis Was made avirulent 
by an inactivating mutation in a cya gene and an inactivating 
mutation in a crp gene. Similar techniques are described in 
other bacteria in US. Pat. Nos. 5,424,065; 5,389,386; 5,387, 
744 and 4,888,170. 
To protect animals from lung disease, it is needed to 
achieve a sufficiently high level of antibodies, particularly 
IgA antibodies, in the lungs to prevent adherence of invading 
microorganisms to mucosal surfaces and neutraliZe poten 
tially damaging virulence factors. Antibodies in the patient’s 
serum or at the mucosal surfaces can be important to 
protection. One of the reasons for using a live vaccine 
instead of a killed Whole cell bacterin is that a live vaccine, 
given intranasally or orally, can induce speci?c local secre 
tory antibody in the secretions that cover mucosal surfaces. 
This local antibody is often quite helpful for protection 
against diseases that infect at or through mucosal surfaces. 
None of the patents pertain to a recombinant technique for 
a relatively convenient method for obtaining genetically 
de?ned mutants for use in a vaccine against APP. 
It is believed that a mutation in a critical biosynthetic 
pathWay Which limits groWth in vivo but does not otherWise 
alter expression of important antigens such as capsular 
polysaccharide, lipopolysaccharide and extracellular toxins, 
could produce an attenuated vaccine strain capable of induc 
ing cross-protective immunity againstA. pleuropneumoniae. 
It is believed that ribo?avin biosynthesis Would be essen 
tial for survival of A. pleuropneumoniae in vivo, and that 
mutations in the ribo?avin biosynthetic pathWay Would be 
attenuating due to the scarcity of ribo?avin present on the 
mucosal surfaces of the respiratory tract. 
It is an object of the present invention to describe the use 
of mutations in the ribo?avin biosynthetic pathWay to con 
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struct attenuated strains of pathogenic bacteria for use as live 
vaccines, With a ribo?avin-requiring mutant of APP used as 
a speci?c example. 
It is an object of the present invention to describe a live 
vaccine against APP utilizing a ribo?avin mutation in the 
APP genome. 
SUMMARY OF THE INVENTION 
Described is a live vaccine against bacterial pathogens 
comprising a recombinant ribo?avin-requiring mutant hav 
ing a mutation that inactivates ribo?avin biosynthesis 
therein. In particular, this includes bacterial pathogens in the 
family Pasteurellaceae, Which include animal pathogens as 
Actinobacillus pleuropneumoniae, Actinobacillus suis, Hae 
mophilusparasuis, Pasteurella haemolytica and Pasteurella 
multocida, as Well as human pathogens Haemophilus in?u 
enzae and Haemophilus ducreyi. 
Also described is a live vaccine against Actinobacillus 
pleuropneumoniae (APP) comprising a recombinant APP 
having an attenuating inactivating mutation therein. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Other advantages of the present invention Will be readily 
appreciated as the same becomes better understood by 
reference to the folloWing detailed description When con 
sidered in connection With the accompanying draWings 
Wherein: 
FIG. 1 describes a proposed a metabolic pathWay for 
bacterial ribo?avin synthesis. 
FIG. 2 is a physical map of a plasmid contruct pTF-10, 
Which comprises a 5.2 Kb fragment of A. pleuropneumoniae 
chromosomal DNA, including the APP ribo?avin biosyn 
thetic operon, cloned into the vector pUC19. 
FIGS. 3A and 3B shoWs the absorbance spectra of aque 
ous solutions at neutral pH (Panel A) and acidi?ed aqueous 
solutions (Panel B) of the product excreted into the groWth 
medium by E. coli DH5ot/pTF10 (solid line) and of a 
standard ribo?avin preparation (dotted line). 
FIGS. 4A to 4D shoW shoWs the complete nucleotide 
sequence of APP ribGBAH operon and ?anking regions and 
the predicted amino acid sequences of the encoded proteins. 
FIG. 5 shoWs the complementation of E. coli ribo?avin 
requiring mutants by cloned APP rib genes. Aphysical map 
for the APP ribGBAH genes is shoWn as Well as several 
deletions. 
FIG. 6 shoWs a minicell analysis of the proteins encoded 
by pTF10 and its deletions. 
FIG. 7 shoWs the construction of pTF67a, a suicide 
delivery vector containing a portion of the APP rib operon 
With a part of ribB and all of ribA deleted and replaced With 
a gene cassette encoding resistance to the antibiotic kana 
mycin. 
FIG. 8A is an analysis of rib-transconjugants of A. pleu 
ropeneumoniae serotype 1 . 
FIG. 8B is a southern blot analysis of chromosomal DNA 
from A. pleuropneumoniae serotype 1 rib mutants. 
DESCRIPTION OF PREFERRED 
EMBODIMENTS 
The present application pertains to the development of 
attenuated mutants of the pathogenic bacterium A. pleurop 
neumoniae Which contain mutations in the genome, speci? 
cally in the genes encoding the enZymes involved in the 
biosynthesis of ribo?avin. By “mutation” is meant not just 
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a random selection of variations of the genome of APP but 
utiliZation of Well knoWn recombinant techniques for spe 
ci?cally modifying the genome of APP. Accordingly, 
therefore, it is desirable to ascertain the ribo?avin biosyn 
thesis genes of APP. 
By “attenuated” is meant a reduction in the severity, 
virulence or vitality of the disease causing agent. 
After determining the sequence and organiZation of the 
ribo?avin genes, one is then able to modify APP by remov 
ing some or all of such genes, thereby attenuating the 
pathogen, i.e., making the pathogen avirulent. 
After a strain of avirulent APP is obtained, it could then 
be utiliZed as a live vaccine. Described beloW are the 
detailed steps broadly outlined above. 
Identifying, Cloning, and Sequencing of the 
Ribo?avin Biosynthesis Genes from APP 
Cloning of ribo?avin genes from APP is described in the 
paper entitled “Characterization of APP Ribo?avin Biosyn 
thesis Genes”, Journal of Bacteriology, December, 1995, 
pages 7265—7270 by Fuller and Mulks. This is incorporated 
herein by reference. 
Actinobacillus pleuropneumoniae (APP) is the causative 
agent of porcine pleuropneumonia (9,23,39). The disease is 
characteristically an acute necrotiZing hemorrhagic 
bronchopneumonia, With accompanying ?brinous pleuritis 
(9,39). Pleuropneumonia is an economically devastating, 
severe and often fatal disease With clinical courses ranging 
from peracute to chronic infection (9,14). The existence of 
at least tWelve antigenically distinct capsular serotypes (31) 
has made development of a cross-protective vaccine dif? 
cult. Killed Whole cell bacterins provide at best serotype 
speci?c protection (25,26,35,43). In contrast, natural or 
experimental infection With virulent APP frequently elicits 
protection against reinfection With any serotype (24,25,27). 
Avirulent strains of APP have been tested as live vaccines 
and have elicited cross-protective immunity against subse 
quent challenge (15,28,44). HoWever, the use of live vac 
cines in the ?eld is problematic, particularly When the 
attenuating lesions in the vaccine strain have not been 
genetically de?ned. Development of attenuated strains With 
de?ned biochemical mutations that limit groWth in vivo and 
prevent reversion to Wild type is a promising approach to 
improved vaccines against APP infection. 
Ribo?avin (vitamin B2), a precursor of the coenZymes 
?avin adenine dinucleotide and ?avin mononucle 
otide (FMN), is essential for basic metabolism. It is synthe 
siZed by plants and by most microorganisms but not by 
higher animals Many pathogenic bacteria are apparently 
unable to utiliZe ?avins from their environment and are 
entirely dependent on endogenous production of ribo?avin 
(38). Therefore, ribo?avin biosynthesis may be essential for 
survival of pathogens in vivo, and mutations in the ribo?avin 
biosynthetic pathWay nay be attenuating. 
The proposed metabolic pathWay for bacterial ribo?avin 
synthesis shoWn in FIG. 1 begins With guanosine triphos 
phate (GTP) as the precursor (for a revieW see reference 1). 
The most extensively studied system for bacterial ribo?avin 
synthesis is Bacillus subtilis (for a revieW see reference 29). 
The B. subtilis ribo?avin synthesis genes are located and 
coregulated in an operon structure (12) that consists of ?ve 
open reading frames designated as ribG, rib B, rib A, ribH 
and ribT (19,29). The ribGBAHT genes encode, 
respectively, a rib-speci?c deaminase; the ot-subunit of 
ribo?avin synthase (lumaZine synthase) a bifunctional 
enZyme containing GTP cyclohydrase and 3,4-dihydroxy 
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2-butanone 4-phosphate synthase (DHBP) activities; the 
[3-subunit of ribo?avin synthase; and a rib-speci?c reductase 
(29). The complete sequence of the B. subtilis ribo?avin 
operon has been determined in tWo individual laboratories 
(19,30). The B. subtilis structural ribGBAHT genes code for 
predicted proteins of 361 (MW 39,700), 215 (MW 23,600), 
398 (MW 43,800), 154 (MW 16,900), and 124 (MW 13,600) 
amino acids in length (19, 29). TWo functional promoters 
have been identi?ed in the B. subtilis rib operon. The main 
promoter, P1, for Which a transcriptional start site has been 
determined 294 base pairs (bps) upstream of ribG (12,30), is 
responsible for transcription of all ?ve structural genes (12). 
Another promoter, P2, produces a secondary transcript 
encoding the last three genes of the operon, ribAHT (12). A 
possible third promoter has been postulated that Would 
express ribH In addition, the operon has been shoWn to 
be transcriptionally coregulated (30) by a transacting 
repressor, RibC (3,6), Which acts at a regulatory site, ribO 
(3,20), upstream of ribG, apparently by a transcription 
termination-antitermination mechanism (29). The RibC 
repressor appears to respond to FMN and FAD, as Well as to 
ribo?avin and several of its biosynthetic intermediates, and 
regulates expression from both ribP1 and ribP2 (4,20,29). 
E. coli is the second most chemically characteriZed sys 
tem for ribo?avin synthesis. In contrast to B. subtilis, the rib 
genes of E. coli are scattered around the chromosome and 
are expressed constituitively (2,46). Rather than having a 
bifunctional ribA, E. coli has tWo separate genes, ribB and 
ribA, that encode the functions of 3,4-DHBP synthase (34) 
and GTP cyclohydrase II (33), respectively. ribB is homolo 
gous to the 5‘ end of B. subtilis ribA While ribA is homolo 
gous to the 3‘ end (33,34). E. coli genes With sequence 
homology to the B. subtilis; ribG (42), ribH (42), and ribB 
genes have also been identi?ed. 
Identi?ed herein is a fragment of APP serotype 5 chro 
mosomal DNA that triggers overproduction of ribo?avin 
When cloned in E. coli. Nucleotide sequence analysis dem 
onstrated four open reading frames With signi?cant identity 
and a similar operon arrangement to the ribGBAH genes 
from Bacillus subtilis. 
Materials and Methods 
Bacterial strains and media. A. pleuropneumoniae 
ISU178, a serotype 5 strain, Was cultured at 37° C. in brain 
heart infusion broth or agar (Difco Laboratories, Detroit, 
Mich.) containing 10 pig/ml nicotinamide adenine dinucle 
otide (NAD) (Sigma Chemical Company, St. Louis, Mo E. 
coli DH5-ot (supE44), AlacU169, (q)80lacZAM15), hsdR17, 
recA1, endA1, gyrA96, thi-1, relA1) Was used for construc 
tion of the APP genomic library. E. coli strain DS410 (aZi-8, 
tonA2, minA1, minB2, rpsL135, xyl-7, mtl-2, thi-1, >\.-) Was 
used for minicell isolation and protein labeling experiments. 
E. coli ribA:Tn5 (BSV18), ribB:Tn5 (BSV11) and ribC:Tn5 
(BSV3) mutants used for complementation studies Were 
described by Bandrin et al (2) and are available from 
Barbara Bachmann coli Genetic Stock Center, Yale 
University). E. coli strains Were cultured in Luria-Bertani 
medium or in M9 (36) supplemented With 15 g/L NZ (amine 
(Sigma) and With ribo?avin at 200 pg/mL When necessary. 
Ampicillin Was added to 100 pig/ml for plasmid selection. 
DNA manipulations. DNA modifying enZymes Were sup 
plied by Boehringer-Mannheim Biochemicals (Indianapolis, 
Ind.) and used according Lo manufacturer’s speci?cations. 
Genomic and plasmid DNA preparations, gel 
electrophoresis, and E. coli transformation Were all per 
formed by conventional methods (36). 
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Cloning and sequencing. APP serotype 5 genomic DNA 
Was digested With HindIII and fragments ranging in siZe 
from 4 to 7 kb Were ligated into the HindIII site in the 
polylinker of the plasmid vector pUC19 (45). Arecombinant 
plasmid, designated pTF10, Which overproduced ribo?avin 
Was isolated from this library. Unidirectional nested dele 
tions Were constructed With exonuclease III and S1 nuclease 
digestion, using the Erase-a base system (Promega Corp., 
Madison, Wis.). Nucleotide sequencing Was performed on 
alkali-denatured double-stranded DNA by the dideoxy 
chain-termination method of Sanger et al. (37) using the 
Sequenase 2.0 kit (U.S. Biochemical, Cleveland, Ohio) and 
[35S]dATP (adenosine triphosphate) (Amersham Corp., 
Arlington Heights, 111.). Sequencing primers used included 
universal forWard and reverse primers for pUC sequencing 
(U.S. Biochemicals), as Well as several oligonucleotide 
primers designed from previously obtained sequence data. 
These internal primers Were synthesiZed by the Michigan 
State University Macromolecular Structure Facility and 
included MM4 (5‘-AAT-CCG-GCA-AAA-NFT-GAA-GGC 
3‘) (Sequence ID No:1), MM5 (5‘-GCA-CCG-TGA-CGC 
ACT-AAC-G-3‘) (Sequence ID No: 2), MM6 (5‘-GCG 
CCA-ATA-CTT-GCT-CAC-CG-3‘) (Sequence ID No: 3), 
MM9 (5‘-GGT-TTC-TTT-ATT-CGT-ATG-CGG-3‘) 
(Sequence ID No: 4), MM10 (5‘-TCA-AGA-AGT-CGG 
CAA-ATT-GCT-C-3‘) (Sequence ID No: 5), MM11 (5‘ 
CGG-ATT-GGG-ATT-CGT-CCA-GCC-3‘) (Sequence ID 
No: 6), MM13 (5‘-GGC-C-AC-ACG-ATT-GCG-GTG-3‘) 
(Sequence ID No: 7), MM14 (5‘-GCC-AGT-TAG-TGC 
AGA- CAG-CG-3‘) (Sequence ID No: 8), and MM38 (5‘ 
CTC-ACC-GGT-TCC-TGC-CAA-ACC-3‘) (Sequence ID 
No: 9). 
DNA sequences Were analyZed using the GCG sequence 
analysis programs (11). 
Mass spectroscopy. Positive and Negative Ion Fast Atom 
Bombardment mass spectroscopy Was performed at 
the Michigan State University Mass Spectroscopy Facility. 
Quanti?cation of ribo?avin. Bacterial cells Were pelleted 
in a microcentrifuge, and the absorbance at 445 nm of the 
culture supernatant Was measured using a Beckman DU-7 
spectrophotometer (Beckman Instruments, Fullerton, 
Calif.). The absorbance at 445 nm Was multiplied by a factor 
of 31.3 to yield the ribo?avin concentration in mg/liter (10). 
Minicell Analysis. The minicell-producing E. coli strain 
DS410 (32) Was transformed by calcium chloride/heat shock 
treatment With pUC19 or pTF rib clones. Transformant 
colonies Which produced a large number of minicells Were 
selected by microscopy. Cultures Were groWn overnight at 
37° C. in 500 mL LB broth, and minicells Were isolated by 
differential centrifugation folloWed by glass ?ber ?ltration 
as described by Christen et al Minicells Were resus 
pended to an OD590 of 0.5—1.0 in 200 pl labeling mix (22.0 
ml M9 media, 20.0 ml 50 mM HEPES (N-[2-hydroxyethyl] 
piperaZine)-N‘-2 ethanesulfonic acid) pH 7.5, 2.5 ml of 20% 
glucose, 0.05 ml of 10 mg/ml adenine, 0.05 ml of 10 mg/ml 
pyridoxine, 5.0 ml of NEDA amino acid stock (21) lacking 
methionine and cysteine, and 0.2 ml of 10 mg/ml 
cycloserine-D) and incubated at 37° C. for 30 minutes. 
Trans-label ([35S]methionine plus [35S]cysteine, ICN 
Biomedicals, Irvine, Calif.) Was added to a ?nal concentra 
tion of 22 pCi per reaction and cells Were incubated at 37° 
C. for 1 hour. Total and TCA (trichloroacetic acid) precipi 
table counts Were measured by liquid scintillation counting 
to determine amount of incorporation. Cells Were pelleted in 
a microcentrifuge and Washed With cold HEPES (50 
mM,pH7.5) plus 10 mM methionine plus 10 mM cysteine. 
Labeled proteins (50,000 cpm/lane) Were separated by dis 
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continuous SDS-PAGE on a 12% polyacrylamide gel and 
Were visualized by autoradiography on Kodak XAR-5 ?lm. 
Nucleotide sequence accession number. The nucleotide 
sequence of the A. pleuropneumoniae ribGBAH genes has 
been submitted to GenBank and assigned an accession 
number of: U27202. 
Results 
Identi?cation of a ribo?avin producing clone. A genomic 
library of A. pleuropneumoniae serotype 5 DNA Was con 
structed in pUC19 and transformed into E. coli DH5-ot. A 
single clone, designated pTF10 (FIG. 2), containing a 5.2 
kbp insert, Was identi?ed that produced a bright yelloW 
extracellular, Water-soluble compound that ?uoresced under 
ultraviolet light. The compound Was crudely puri?ed by 
?ltration through a 3000 Da cut off membrane ?lter (Amicon 
Corporation, Bedford, Mass.). Absorbance spectra of this 
compound in aqueous solution under neutral conditions 
shoWed absorbance peaks at 373 and 443 nm, Which coa 
lesced to a single peak at 388 nm under acidic conditions; 
these results compared Well to a ribo?avin standard (FIGS. 
3A and 3B). Positive and negative ion fast atom bombard 
ment mass spectroscopy indicated that the compound Was a 
?avin (data not shoWn). Culture of E. coli DH5-ot/pTF10 in 
M9 medium plus NZ amine plus 0.6% glucose yielded 10 
mg ribo?avin per liter in 24 hours. pTF10 Was deposited 
under the terms of the Budapest Treaty at the American Type 
Culture Collection, 10801 University Boulevard, Manassas, 
Va. 20110-2209 on Aug. 31, 2000 as ATCC PTA-2438. All 
restrictions on availability to the public of the deposited 
material Will be irrevocably removed upon granting the 
patent. 
Sequence of APP rib genes. The nucleotide sequence and 
corresponding predicted amino acid sequence of a 4312 bp 
region of the insert in pTF10 is shoWn in FIGS. 4A to 4D. 
Four open reading frames of 1232, 647, 1205, and 461 bp 
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four ORFs Were preceded by potential ribosome binding 
sites (RBS), although the RBS upstream of ribG is not as 
strong as the other three. Production of ribo?avin by this 
clone is not dependent on its orientation in pUC19 or on 
induction by IPTG, indicating that it is produced under the 
control of a native promoter included in the cloned DNA 
fragment. A consensus promoter sequence of the —35/—10 
type (12) Was identi?ed Within the sequenced region 224 bp 
upstream from the ribG start codon. A second potential 
consensus promoter Was identi?ed betWeen the genes ribA 
and ribH. HoWever, no consensus promoter Was identi?ed 
betWeen ribB and ribA, as is found in B. subtilis. The ORF 
encoding ribH is folloWed by an inverted repeat stem-loop 
structure With a AG=—56.0, that may function as a rho 
dependent transcriptional terminator (13). 
Homology of APP rib genes. Predicted amino acid 
sequences of the APP RibGBAH proteins Were compared 
With B. subtilis RibGBAH (19); E. coli RibA, RibB, RibC, 
RibG, and ribH (33,34,42); Photobacterium leiognathi RibI 
III (17), Photobacterium phosphoreum RibI-IV (16), and 
Vibrio harveyi LuXH (41) proteins, using the GCG Gap 
program (Table 1). APP RibG shoWed 62—63% similarity to 
the RibG proteins from B. subtilis and E. coli. APP RibB 
shoWed 58—69% and APP RibH shoWed 69—83% similarity 
to homologous genes from B. subtilis, E. coli, and Photo 
bacterium species. APP RibA shoWed 73% similarity to the 
entire RibA protein of B. subtilis and 61% to the RibII 
protein of R leiognathi, both of Which encode a bifunctional 
enZyme catalyZing tWo distinct steps in the ribo?avin path 
Way. In addition, the carboXy terminal half of APP RibA, 
encompassing ~200 amino acids, shoWs 59—63% similarity 
to E. coli RibB, and V harveyi LuXH, Which encode 3,4 
DHBP synthase. The N-terminal region of APP RibA, 
encompassing the remaining ~200 amino acids, shoWs 
63—73% similarity to E. coli RibA and R phosphoreum 
RibIV, Which encode GTP cyclohydrase II. 
TABLE 1 
Precent similarity of amino acid sequences of ribo?avin synthesis proteinsa 
% Similarity With A. pleuropneumoniae 
RibG RibB RibA RibH 
Compared Compared Compared Compared 
Bacterium With % With % With % With % 
B. subtilis RibG 63 RibB 69 RibA 73 RibH 83 
E. colib RibG 62 RibC 58 RibB 63 RibH 74 
RibA 73 
H. in?uenzaec RibG 58 RibC 60 RibB 65 RibE 75 
RibA 71 
R leiognathi NA RibI 64 RibII 61 RibIII 69 
R phosphoreum‘i NA RibI 63 RibII 59 RibIII 73 
RibIV 63 
V harveyi NA NA LuXH 59 NA 
aIdentity is expressed in percent similarity as calculated by the Genetics Computer Group 
Needleman-Wunsch algorithm (22). Proteins With partial identify Were compared With the entire 
appropriate A. pleuropneumoniae Rib protein. 
bE. coli RibB is homologous to the 5' end ofA. pleuropneumoniae RibA. E. coli RibA is 
homologous to the 3' end ofA. pleuropneumoniae RibA. 
CH. in?uenzae RibB is homologous to the 5' end of A. pleuropneumoniae RibAH. in?uenzae 
RibA is homologous to the 3' end ofA. pleuropneumoniae RibA. 
‘1R phosphoreum RibIV is homologous to the 3' end of A. pleuropneumoniae RibA. 
Were observed that encoded proteins With predicted molecu 
lar masses of 45,438 Da, 23,403 Da, 44,739 Da and 16,042 
Da, respectively. Based on homology With the ribo?avin 
biosynthetic genes of B. subtilis (see beloW), these ORFs 
Were designated ribG, ribB, ribA, and ribH, respectively. All 
65 
Complementation of E. coli mutants. The original pTF10 
clone and several deletion derivatives Were tested for their 
abilities to complement ribA (GTP cyclohydrase II), ribB 
(3,4-DHBP synthase), and ribC ([3-subunit of ribo?avin 
synthase) mutations in E. coli (2) (FIG. 5) Complementation 
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of the E. coli mutation Was determined by restoration of the 
ability to groW on M9 minimal medium in the absence of 
ribo?avin. Plasmids containing a complete copy of the APP 
ribB gene complemented the E. coli ribC mutation. Plas 
mids containing the 5 ‘ end of APP ribA complemented the E. 
coli ribB mutation. Plasmids containing a complete copy of 
APP ribA complemented both E. coli ribB and ribA muta 
tions. 
Minicell analysis. Plasmid pTF10 and its deletion deriva 
tives Were transformed into the minicell-producing E. coli 
strain DS410, and the proteins encoded by these plasmids 
Were radioactively labeled, separated by SDS-PAGE, and 
visualiZed by autoradiography. Compared With the pUC19 
vector, plasmid pTF10 shoWs four unique proteins With 
apparent molecular masses of 45 kDa, 27.7 kDa, 43.7 kDa, 
and 14.8 kDa (FIG. 6), Which correspond Well With the siZes 
predicted for the RibG, RibB, RibA, and RibH proteins by 
amino acid sequence data. The RibG protein did not appear 
to be as strongly expressed as RibB, RibA, and RibH. 
Analysis of proteins encoded by plasmid pTF19 (FIG. 5), 
Which contains no ribH and a slightly truncated ribA gene, 
eliminates the 14.8 kDa protein (RibH) and truncates the 
43.7 kDa protein (RibA) to 42.5 kDa (FIG. 6). Plasmid 
pTF12 (FIG. 5), Which does not contain ribB, ribA, or ribH 
genes, does not express the 27.7, 43.7, or 14.8 kDa proteins 
(data not shoWn). 
Described above is the identi?cation, cloning and com 
plete nucleotide sequence of four genes from Actinobacillus 
pleuropneumoniae that are involved in ribo?avin biosynthe 
sis. The cloned genes can specify production of large 
amounts of ribo?avin in E. coli, can complement several 
de?ned genetic mutations in ribo?avin biosynthesis in E. 
coli, and are homologous to ribo?avin biosynthetic genes 
from both E. coli and Bacillus subtilis. The genes have been 
designated APP ribGBAH due to their similarity in both 
sequence and arrangement to the B. subtilis ribGBAH 
operon. 
The DNA sequence data, complementation, and minicell 
analysis strongly suggest that the four rib genes are tran 
scribed from a single APP promoter upstream of the ribG 
gene. This promoter, among the ?rst described for house 
keeping genes in APP, is a good match for an E. coli 
consensus —35/—10 promoter. There is a 4 of 6 bp match at 
the —35 region, a 17 bp interval, a 4 of 6 bp match at the —10 
region, an 8 bp interval, and a CAT box at the —1/+1 site. 
There is also a second potential promoter located betWeen 
ribA and ribH, although it is not clear Whether this promoter 
is functional. 
Biosynthesis of ribo?avin by APP appears to be more 
similar to that in the gram-positive bacterium B. subtilis than 
in the gram-negative bacterium E. coli . First, APP rib genes 
are arranged in an operon similar to that seen in B. subtilis, 
rather than scattered throughout the chromosome as is found 
in E. coli . HoWever, the B. subtilis rib operon contains a ?fth 
gene, ribT, that is proposed to mediate the third step in 
ribo?avin biosynthesis; it is unlikely that a ribT homologue 
is present as part of the operon in APP because of the 
presence of a strong inverted repeat folloWing ribH and the 
lack of a likely reading frame doWnstream. Second, APP 
contains a ribA gene that encodes a bifunctional enZyme 
With both GTP cyclohydrase II and DHPB synthase 
activities, as is found in B. subtilis,' E. coli has tWo genes, 
ribA and ribB, that encode these tWo enZymes separately. 
Finally, the APP ribo?avin biosynthetic enZymes are more 
similar at the amino acid level to the enZymes of B. subtilis 
than to those of E. coli, although alignment of the proteins 
from all three sources shoWs highly conserved sequences 
(data not shown). 
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It should be noted that in three bioluminescent species 
from the family Vibrionaceae, Vibrio harveyi, Photobacte 
rium leiognathi, and R phosphoreum, ribo?avin biosynthe 
sis genes have been shoWn to be closely linked to the lux 
operon (10, 11, 41). FMNH2 is the substrate for the light 
emitting reaction, and therefore an increase in biolumines 
cence requires an increased supply of the cofactor. Since 
ribo?avin is the precursor for FMN, linkage and possibly 
coordinate regulation of lux and rib genes may facilitate the 
expression of bioluminescence in these bacteria. 
The recombinant E. coli DH5-ot containing plasmid 
pTF10 shoWed a marked increase in extracellular ribo?avin 
production, most likely due to the lack of regulation (40) and 
high copy number of the cloned synthetic genes (45). 
Although the APP rib operon is similar in structure to that of 
B. subtilis, it is not yet knoWn Whether the genes are tightly 
regulated in APP by a repressor similar to B. subtilis RibC, 
or Whether they are constituitively expressed as appears to 
be true in E. coli (33). It is believed APP must synthesiZe 
ribo?avin to meet its oWn metabolic demands during 
infection, since ribo?avin is not synthesiZed by mammals 
and therefore is not likely to be freely available to APP 
Within its porcine host. 
Attenuation of Rib-Mutants of A. 
pleuropneumoniae 
Applicants have constructed deletion-disruption 
ribo?avin-requiring mutants of A. pleuropneumoniae sero 
types 1 and 5. 
Applicants have conducted experiments to con?rm that 
the Rib-APP mutants constructed are attenuated in sWine. 
In a preliminary experiment, seven 8-to-10 Week old pigs 
Were used. Three pigs Were infected endobronchially With 
NalR (resistant to the antibiotic malidixic acid) derivatives of 
Wild type virulent APP-1 or APP-5; three Were infected With 
APP-5 Rib-mutants; and one Was used as an uninfected 
control. The APP strains, dosages used for infection, and 
results are summariZed beloW in Table 2. Animals Were 
euthaniZed When clinical signs became severe or at 12 hours 
post infection. The animals Were necropsied and the lungs 
examined for gross pathology and histopathology, and lungs 
Were cultured to recover APP. 
TABLE 2 
Summary of clinical signs, gross pathology, and 
histopathology seen in pigs challenged With either Wide 
type APP serotvpe 1 or 5 or Rib- mutants of App Serotvpe 5 
APP Strain 
and Description Dosage Results 
AP225: APP-1, NalR 2 x 108 cfu Died, <4 hrs; 4+ peracute 
hemorrhagic pneumonia lesions 
AP227: APP-5, NalR 1 x 109 cfu Died, <4 hrs: 4+ peracute 
hemorrhagic pneumonia lesions 
AP228: APP-5, NalR 1 x 109 cfu Died, <4 hrs: 4+ peracute 
hemorrhagic pneumonia lesions 
AP229: APP-5, NalR', 1 x 109 cfu Mild clinical signs; 1+ mild 
KmR, Rib- pneumonia lesions 
AP230: APP-5, NalR', 1 x 109 cfu Mild clinical signs; 1+ mild 
KmR, Rib- pneumonia lesions 
AP231: APP-5, NalR', 1 x 109 cfu Mild clinical signs; 1+ mild 
KmR, Rib- pneumonia lesions 
None — 1+ mild pneumonia lesions 
(mycoplasma?) 
Note that the dosage used in all of these animals Was 
about 200 times the LD5O(50% lethal dose, or the dose that 
Will kill 50% of the animals exposed) for the Wt (Wild type) 
US 6,410,021 B1 
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APP parent strains. The NalR derivatives of the Wild type) 
parent strains retained virulence, triggering severe ?brino 
suppurative hemorrhagic pneumonia and death Within 4 
hours. The Rib- mutants caused minimal clinical signs 
(increased respiration rate and slight fever) and at most mild 
signs of pneumonia, including some consolidation but no 
hemorrhagic necrosis, as compared to the uninfected con 
trol. These Were not SPF (speci?c pathogen free) pigs, and 
there Were histologic lesions suggestive of mild mycoplasma 
infection, in all of the pigs, including the uninfected control 
(Table 2). 
Described beloW is the construction of a deletion 
disruption ribo?avin mutant of A. pleuropneumoniae sero 
type 1 (APP-1) and detailed analysis of the attenuation of 
this APP-1 Rib-mutant in vivo in sWine. 
Materials and Methods 
Bacterial strains and media. The bacterial strains and 
plasmids used in this study are listed in Table 1. A. pleu 
ropneumoniae strains Were cultured at 37° C. in either brain 
heart infusion (BHI), heart infusion (HI), or tryptic soy agar 
(TSA) (Difco Laboratories, Detroit, Mich.) containing 10 
pig/ml NAD (V factor) (Sigma Chemical Company, St. 
Louis, Mo.). Ribo?avin (Sigma) Was added to a ?nal con 
centration of 200 pig/ml When needed. E. coli strains Were 
cultured in Luria-Bertani medium. Ampicillin Was added to 
100 pig/ml and kanamycin to 50 pig/ml for plasmid selection 
in E. coli strains. ForA. pleuropneumoniae strains, 50 pig/ml 
kanamycin sulfate and 25 pig/ml nalidixic acid Were added as 
required, except for selection after matings Which Were 
performed With 100 pig/ml kanamycin sulfate and 50 pig/ml 
nalidixic acid. 
DNA manipulations. DNA modifying enZymes Were sup 
plied by Boehringer-Mannheim Biochemicals (Indianapolis, 
Ind.) and used according to the manufacturer’s speci?ca 
tions. Genomic DNA Was prepared according to the lysis/ 
proteinase K method of the Gene Fusion Manual (Silhavy, 
T. J. 1984. DNA extraction from bacterial cells. p. 137—139. 
In Experiments With Gene Fusions. Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY. 34). Plasmid DNA 
preparations, agarose gel electrophoresis, and E. coli trans 
formation Were all performed by conventional methods 
(Sambrook, J ., E. F. Fritsch and T. Maniatis. 1989. Molecu 
lar Cloning: A Laboratory Manual, 2nd. ed. Cold Spring 
Harbor Press, Cold Spring Harbor, NY). 
Filter mating targeted mutagenesis. Filter mating betWeen 
E. coli S17-1 ()tpir)/pTF67A and AP225 Was performed 
according to the protocol of Mulks and Buysse (Mulks, M. 
H. and J. M. Buysse. 1995. A targeted mutagenesis system 
for Actinobacillus pleuropneumoniae. Gene 165 :61—66). 
Brie?y, bacterial cultures Were groWn overnight at 37° C. 
Equal cell numbers of donor and recipient cultures, as 
determined by optical density at 520 nm, Were added to 5 ml 
10 mM MgSO4 and the bacteria pelleted by centrifugation. 
The pellet containing the cell mating mixture, resuspended 
in 100 pl of 10 mM MgSO4, Was plated on a sterile ?lter on 
BHIV+ribo?avin agar and incubated for 3 h at 37° C. Cells 
Were Washed from the ?lter in sterile phosphate buffered 
saline (pH 7.4), centrifuged, resuspended in 400 pl BHIV 
broth and plated in 100 pl aliquots on BHIV containing 
ribo?avin, kanamycin, and nalidixic acid. Kanamycin and 
nalidixic acid resistant colonies Were selected from ?lter 
mating plates and screened for ribo?avin auxotrophy by 
replica plating onto TSAV, observing for inability to groW in 
the absence of added ribo?avin. 
Southern Analysis of Transconjugants. Chromosomal 
DNA and plasmid controls Were digested With the appro 
15 
25 
35 
45 
55 
65 
14 
priate restriction enZymes and the DNA fragments Were 
separated on an 0.7% ultrapure agarose gel in TAE buffer. 
Southern blots Were performed as described by Sambrook et 
al (Sambrook, J ., E. F. Fritsch and T. Maniatis. 1989. 
Molecular Cloning: A Laboratory Manual, 2nd. ed. Cold 
Spring Harbor Press, Cold Spring Harbor, NY). DNA 
probes Were labeled With digoxygenin by random priming 
using the Genius V. 3.0 kit from Boehringer Mannheim. 
Probes included the 5.2 Kb insert from pTF10 containing the 
intact ribo?avin operon from AP106 (Rib), the 1.4 Kb 
ClaI/NdeI fragment deleted from the ribo?avin operon in the 
construction of pTF67a (R.Del.), the 1.2 Kb kanamycin 
cassette from pUC4K and the intact plasmid pGP704 
(pGP704). HybridiZation Was carried out in 50% formamide 
at 42° C. for 16 h. Blots Were Washed tWice in 2><SSC/0.1% 
SDS for 15 min at room temperature, then tWice in 0.1>< 
SSC/0.1% SDS for 30 min at 65° C. Blots Were developed 
With alkaline phosphatase-conjugated anti-digoxygenin and 
colorimetric substrate (Boehringer Mannheim) according to 
the manufacturer’s instructions. 
Phenotypic analysis of mutant strains. Whole cell lysates 
and supernatants of AP100, AP225 (NalR), and AP233 
(KmR, NalR, Rib-) Were prepared from overnight cultures 
groWn in HIV+5 mM CaCl2+appropriate antibiotics. 
APP225 and APP33 Were deposited under the terms of the 
Budapest Treaty at the American Type Culture Collection on 
Aug. 31, 2000 as ATCC PTA-2429 and ATCC PTA-2430, 
respectively. All restrictions on availability to the public of 
the deposited material Will be irrevocably removed upon 
granting the patent. Cells Were separated by microcentrifu 
gation and resuspended in SDS-PAGE sample buffer 
(Laemnli, UK. 1970. Cleavage of structural proteins during 
the assembly of the head of bacteriophage T4. Nature 
227:680—685). The culture supernatant Was precipitated 
With an equal volume of 20% trichloroacetic acid (TCA) and 
resuspended in SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) sample buffer. Cellular 
polysaccharides, including lipopolysaccharide (LPS) and 
capsular polysaccharide, Were prepared according to the cell 
lysis/proteinase K method of Kimura et al (Kimura, A. and 
E. J. Hansen. 1986. Antigenic and phenotypic variations of 
Haemophilus in?uenzae type B lipopolysaccharide and their 
relationship to virulence. Infect. Immun. 51:69—79) . All 
samples Were analyZed on a 0.125% SDS-12% acrylamide 
gel using a discontinuous buffer system (Laemmli, UK. 
1970. Cleavage of structural proteins during the assembly of 
the head of bacteriophage T4. Nature 227:680—685). 
Samples Were transferred to nitrocellulose according to 
standard protocols (Sambrook, J ., E. F. Fritsch and T. 
Maniatis. 1989. Molecular Cloning: A Laboratory Manual, 
2nd. ed. Cold Spring Harbor Press, Cold Spring Harbor, 
NY.) and probed With convalescent serum from a pig 
infected With A. pleuropneumoniae serotype 1. Antigen 
antibody complexes Were detected With horseradish 
peroxidase-conjugated protein A (Boehringer Mannheim) 
and the calorimetric substrate 4-chloro-naphthol (BioRad, 
Hercules, Calif.). 
Production of serotype-speci?c capsular polysaccharide 
Was measured by coagglutination assay using hyperimmune 
rabbit anti-sera complexed to Staphylococcus aureus Whole 
cells (Jolie, R. A. V., M. H. Mulks, and B. J. Thacker. 1994. 
Antigenic differences Within Actinobacillus pleuropneumo 
niae serotype 1. Vet. Microbiol. 38:329—349). 
Electroporation of A. pleuropneumoniae. AP233 Was 
groWn in 100 ml BHIV With ribo?avin at 37° C., With 
shaking at 150 RPM, to an OD520 of 0.7. Cells Were chilled 
on ice and centrifuged at 5,000><g at 4° C. for 10 min. Cells 





















